Form 4: Cross Country Healthcare CIO Receives Equity Grant

Cross Country Healthcare's Chief Information Officer, Phillip Lyn Noe, was granted 12,826 restricted shares of common stock.

Summary

• Phillip Lyn Noe, Chief Information Officer of Cross Country Healthcare Inc. (CCRN), acquired 12,826 restricted shares of common stock on December 18, 2025.
• The shares were granted at a price of $0, indicating an equity award rather than a purchase.
• Following this transaction, Mr. Noe beneficially owns a total of 23,146 shares.
• These restricted shares (RSAs) will vest in three substantially equal installments on December 18, 2026, March 31, 2027, and March 31, 2028.
• The Compensation Committee approved the grant date of December 18, 2025, instead of March 31, 2025, following the termination of a merger agreement with Aya Holdings II Inc., Spark Merger Sub One Inc., and Aya Healthcare, Inc. on December 3, 2025.
• The subsequent vesting dates are aligned with the company's previously granted RSAs.

Sentiment

Score: 7

Explanation: The filing reflects a standard executive equity grant, which is generally positive for aligning management incentives. The context of a terminated merger is a past event, but the grant itself is a routine compensation action.

Positives

• The grant of restricted shares to a key executive aligns management's interests with those of shareholders, incentivizing long-term performance.
• The equity award is a standard component of executive compensation, reflecting ongoing commitment to the company's leadership.

Negatives

• The grant date was adjusted due to the termination of a merger agreement with Aya Holdings II Inc., Spark Merger Sub One Inc., and Aya Healthcare, Inc., which occurred on December 3, 2025.

Risks

• The restricted shares are subject to a vesting schedule, meaning the executive must remain employed by the company through the vesting dates to fully realize the benefit of the grant.
• The value of the shares is subject to market fluctuations, and the ultimate value realized by the executive depends on the company's stock performance.

Future Outlook

The vesting schedule for the restricted shares extends through March 2028, indicating a long-term incentive structure for the Chief Information Officer and a commitment to future performance.

Management Comments

• The Compensation Committee of the Company's Board of Directors approved the number of RSAs to be granted on December 18, 2025, instead of March 31, 2025, following the termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025.
• After the initial vesting date 12 months from the grant date, the remaining RSAs will vest on March 31 of the two subsequent years to coincide with the vesting dates of the Company's previously granted RSAs.

Industry Context

Equity grants to key executives are a standard practice in the healthcare staffing and broader corporate sectors, used to attract, retain, and incentivize leadership. The re-timing of the grant due to a terminated merger highlights the dynamic nature of corporate strategic initiatives and their impact on compensation planning.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) or restricted shares (RSAs) at a $0 exercise price is a common form of equity compensation for executives across various industries, including healthcare services.
• Vesting schedules over multiple years are typical for such grants, aiming to align executive incentives with long-term shareholder value creation, similar to practices at peers like AMN Healthcare Services or HealthEquity.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the Chief Information Officer's financial interests with long-term shareholder value, potentially leading to improved performance. It also represents a minor dilution of existing shares over time as the shares vest.
• Employees: This grant is part of the executive compensation structure, which can influence overall compensation philosophy and morale within the company.

Next Steps

• The restricted shares will vest in three installments on December 18, 2026, March 31, 2027, and March 31, 2028.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive, which is a standard compensation practice. While it aligns management's interests with shareholders, it does not introduce new fundamental information or significant strategic shifts that would warrant a change in investment recommendation based solely on this disclosure. The mention of a terminated merger is contextual for the grant date change, but the merger termination itself is a past event.

Keywords

Cross Country Healthcare, CCRN, Phillip Lyn Noe, Chief Information Officer, Restricted Stock, Equity Grant, Insider Transaction, Form 4, Executive Compensation, Vesting